Antithrombin III Deficiency
7
0
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
14.3%
1 terminated out of 7 trials
66.7%
-19.8% vs benchmark
29%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Belgian Antithrombin Deficiency Registry
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
Antithrombin III in Infectious Disease Caused by COVID-19
Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO
Atenativ Effect on Uterine Blood Flow and Preeclampsia
"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"
Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery